Phase diagrams of four binary blends of polyisobutylene (component 1) and deuterated polybutadiene (component 2) were determined using small-angle neutron scattering (SANS). Our study covers N1/N2 ...

Using the Flory−Huggins parameter and a previously measured value of the Maier−Saupe parameter, the PPV-b-PI phase diagram may be converted from system-specific variables to dimensionless parameters.

As the number of particles in a physical system increases, its properties can change and different phase transitions (i.e., ...

INmune Bio's XPro1595 targets soluble TNF for Alzheimer's. Phase 2 results could reshape inflammatory disease treatment. Click to read.

President Donald Trump said Tuesday that he plans to phase out the Federal Emergency Management Agency after this year’s hurricane season, offering the clearest timeline yet for his ...

Claudin-18 isoform 2 (CLDN18.2) has emerged as a promising therapeutic target in gastric or gastro-oesophageal junction cancer. Satricabtagene autoleucel (satri-cel; also known as CT041), an ...

In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to ...

Otsuka Pharmaceuticals’ investigational antibody sibeprenlimab significantly lowered urinary protein levels in patients with immunoglobulin A nephropathy in a Phase III trial, the company reported ...

ENLIGHTED phase 3 study: Interim results of efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) in the treatment of low-grade upper tract urothelial cancer (LG UTUC). This ...

Methods: NIVOPOSTOP is an international randomized, open-label Phase 3 trial (NCT03576417). Main inclusion criteria were patients < 75 years, ECOG PS 0-1, with resected LA-SCCHN of the oral cavity, ...

Southern California’s air quality regulators are set to vote this week on new rules aimed at phasing out the sale of gas-powered furnaces and water heaters in the region.

Moonlake is running phase 3 studies of the nanobody in psoriatic arthritis and advancing the drug candidate toward pivotal trials in psoriasis, palmoplantar pustulosis and axial spondyloarthritis.